Wednesday, March 27, 2013

Flex Facilities Session Spotlight: Flex Facilities: Flexible Bioproduction Strategies for Vaccines, Pandemics and Biothreats

Having the ability to ramp up or down production of a biological or vaccine on demand is of great interest to biomanufacturing companies. The flexibility this provides in the case of a sharp increase or decrease in demand of your vaccine decreases the overall project risk. And in the case of a pandemic or biothreat, having the ability to quickly manufacture an agent to counteract these situations can have a huge benefit in saving lives. Next week at the Flexible Facilities event, several sessions will focus on Flex Facilities: Flexible Bioproduction Strategies for Vaccines, Pandemics and Biothreats.  They will describe the flexible bioproduction factories emerging around the world that offer these capabilities.

Flexible Facilities will take place next week, April 2-4, 2013 in San Francisco, California.  For more information on this event, download the agenda.  If you'd like to join us, as a reader of this blog, mention code FF13JP when you register and you'll save 20% off the standard rate.

Featured session: Increasing Flexibility in Vaccine Manufacturing Processes and Facilities with Disposable/Single-Use Technologies

Featured Speaker: Tony D’Amore, Ph.D., Vice President, Bioprocess Research & Development, North America, Sanofi Pasteur, Canada

About the session: This presentation discusses specific examples of the use of single-use disposable technologies in the downstream purification and the formulation and filling of our vaccine clinical products. In addition to increasing the speed of process development, single-use disposable technologies are less technically complex, have lower investment costs and offer a wide variety of flexibility and ease in facility change-over.

Featured Session: Case Study of a Flexible, Multi-Product Vaccine Facility: Medigen, Taiwan

Featured Speakers: Niels Guldager, Senior Technology Partner, NNE Pharmaplan, Denmark
Klaus Hermansen, Senior Technology Partner, NNE Pharmaplan, Denmark

About the session: Medigen is a company that is planning to produce a number of different vaccine products in a new green field facility in Taipei, Taiwan.

This case study discusses:
  • - Level of flexibility required for two production lines
  • - Changeover from BSL2 to non-BSL functions of various process areas
  • - Uni-directional flow as a tool for process segregation; Modular versus nonmodular facility design
  • - Manufacturing logistic challenges by operation in a multi-product facility

Share this article with your social network, just click below to share now!

No comments :

Post a Comment